A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
Insider Insights: Unveiling Takeaways from AACR 2024
Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
Dual Checkpoint Inhibition Leads to Higher Response Rates vs Anti-PD1 Therapy in High-Risk Resectable Melanoma
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Florida Cancer Specialists & Research Institute Expands Access To Cancer Care in Volusia County
Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC